Immunome Q2 net loss $43.4M; cash $268M; varegacestat Phase 3 topline data by end 2025

Immunome Inc.

2025-Q2 EPS reported -$1.02 vs consensus -$0.54 ▼ miss (-89.1%)

Net loss of $43.4M for Q2 2025; cash, equivalents and securities $268M as of June 30.
R&D expenses $40.5M, G&A $10.0M; cash expected to fund operations into 2027.
Varegacestat Phase 3 RINGSIDE Part B topline data expected before end of 2025; EMA granted Orphan Drug Designation in July 2025.
IM-1021 Phase 1 trial dosing at third dose level; IM-3050 IND cleared April 2025, Phase 1 start expected by end 2025.
Three preclinical ADCs (IM-1617, IM-1340, IM-1335) undergoing IND-enabling work; additional undisclosed ADCs in discovery.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.